Benefits
Bulk sugar replacement with zero glycemic impact
About 60-70% as sweet as sucrose with near-zero calorie content (commonly labeled as 0.2-0.5 kcal/g). Glycemic index near zero — does not raise blood glucose or insulin. Bulk-replacement properties (similar volume to sugar) make it useful in baking and beverages where high-intensity sweeteners alone don't provide texture.
Cardiovascular event association (concerning)
A 2023 Nature Medicine study showed elevated blood erythritol associated with major adverse cardiovascular events over 3 years, confirmed across 2 independent cohorts of over 4,000 adults. Important caveat: erythritol is endogenously produced (especially in metabolic disease), so the observational signal is partially confounded by underlying metabolic state.
Acute platelet activation in healthy volunteers
A 2024 follow-up study showed a single 30 g erythritol dose in healthy adults caused rapid platelet activation and increased thrombosis biomarkers versus glucose control. Effect peaked around 30 minutes post-dose and returned to baseline by 4 hours. Industry has challenged the clinical relevance of single-bolus dosing far above food exposure.
Endogenous production confounder
Erythritol is produced endogenously from glucose via the pentose phosphate pathway. Production is elevated in diabetes, obesity, and metabolic syndrome — the same conditions associated with cardiovascular risk. Suggests the observational cardiovascular signal may be partially driven by underlying metabolic state. Genuinely confounded but not fully explanatory.
Regulatory status — currently unchanged
FDA Generally Recognized as Safe (GRAS) status maintained. EU EFSA approved. WHO 2023 non-sugar sweetener guidance includes erythritol with caution but no specific restriction. Industry response to recent findings emphasizes dose context and observational study limitations.
Better GI tolerance than other polyols
About 95% absorbed in the small intestine, then excreted unchanged in urine. Most polyols (sorbitol, xylitol, mannitol) cause osmotic diarrhea at much lower doses. Erythritol's GI threshold is roughly 50 g single dose versus 20 g for sorbitol. Practical advantage for sugar-free product formulation.
Dental health — non-cariogenic
Streptococcus mutans cannot ferment erythritol — does not contribute to dental caries. Some preliminary evidence suggests erythritol may modestly reduce caries when used in chewing gums or candies. Not as well-established as xylitol for dental applications but a reasonable component of sugar-free oral products.
Practical interpretation
Erythritol remains regulatory-approved and within ADI. The 2023-2024 cardiovascular findings warrant attention but don't currently override food-level use. Reasonable approach: moderate exposure from products is acceptable; concentrated supplementation or daily heavy use may carry uncertain risk pending more research.
Mechanism of action
Small-intestine absorption and renal excretion
Erythritol is absorbed by passive diffusion across the small intestine at ~90% efficiency — unusually high for a polyol due to its small molecular size (4 carbons, MW 122). Once absorbed, humans lack the enzymatic machinery to metabolize erythritol; it circulates in plasma and is excreted essentially unchanged in urine within 24 hours. This non-metabolism is the basis for the ~0.2 kcal/g caloric value and the zero glycemic effect.
Endogenous synthesis via pentose phosphate pathway
Erythritol is produced endogenously from glucose-6-phosphate via the pentose phosphate pathway — particularly active during metabolic stress, hyperglycemia, and oxidative conditions. Plasma erythritol can be elevated in people with diabetes or obesity even without dietary erythritol intake. Important confounder in interpreting the 2023 observational study, partially addressed by the 2024 acute-ingestion trial which controlled for endogenous baseline.
Platelet activation at observed plasma concentrations
In vitro experiments in the 2023 Nature Medicine paper showed erythritol at concentrations achieved in patients with high dietary intake (low millimolar range) enhanced platelet aggregation in response to ADP and other physiological agonists. Mouse experiments showed faster clot formation in arterial injury models with elevated circulating erythritol. The 2024 follow-up showed 30 g oral erythritol in healthy humans achieves plasma concentrations roughly 1700× higher than baseline endogenous levels — well into the range that activates platelets in vitro.
Sweet taste and cooling mouthfeel
Erythritol activates the T1R2/T1R3 sweet taste receptor at lower potency than sucrose (~70% sweetness). Endothermic dissolution (erythritol absorbs heat as it dissolves) produces a distinctive cooling mouthfeel — useful in mints and chewing gum but often perceived as unpleasant in baked goods, prompting the use of stevia/monk fruit blends to reduce required erythritol mass.
Antioxidant properties (mechanistic interest, unclear clinical relevance)
In vitro studies have documented modest antioxidant activity for erythritol. This was historically cited as a positive feature but is mechanistically separate from — and does not offset — the platelet-activation findings. Antioxidant activity in a test tube does not prevent platelet aggregation in a human bloodstream.
Clinical trials
Three-cohort study from Cleveland Clinic Hazen lab. Untargeted metabolomics in 1,157 cardiac patients identified erythritol as a polyol sweetener associated with 3-year MACE (death, MI, stroke). Targeted validation in US (n=2,149, NCT00590200) and European (n=833, DRKS00020915) cohorts confirmed the association: highest vs. lowest plasma erythritol quartile adjusted hazard ratios were 1.80 (95% CI 1.18-2.77) and 2.21 (95% CI 1.20-4.07). Mechanistic platelet aggregation and mouse thrombosis data supported a plausible causal pathway. Limitation: observational design, populations were already cardiac patients undergoing evaluation. Funded by NIH NHLBI, ODS, and other agencies.
Prospective intervention in healthy volunteers comparing 30 g erythritol vs. 30 g glucose ingestion. Erythritol produced a >1000-fold plasma erythritol increase (~3.75 → ~6,480 μmol/L) and acute enhanced platelet reactivity and thrombosis potential markers. Glucose did not. Confirmed that dietary erythritol at typical keto-product serving sizes acutely activates platelets in healthy people — converts the 2023 observational signal into an interventional finding consistent with causation.
RCT in 485 first-grade children randomized to erythritol-, xylitol-, or sorbitol-sweetened candies for 3 years. Erythritol-group children had lower caries incidence than xylitol or sorbitol groups. Established erythritol as a non-cariogenic sweetener, supporting its dental-product applications.
Critical evaluation of the Witkowski 2023 paper raising the endogenous-erythritol confounder argument. Authors acknowledged the original paper did not overstate findings but argued dietary causation was not established by observational data alone. Argument is partially weakened by the 2024 Witkowski acute-ingestion trial showing dietary erythritol does activate platelets independent of underlying metabolic disease.